Kintara Therapeutics, Inc. (KTRA)
After hours:
| Previous Close | 0.1572 |
| Open | 0.1565 |
| Bid | 0.1502 x 1200 |
| Ask | 0.1544 x 4100 |
| Day's Range | 0.1499 - 0.1624 |
| 52 Week Range | 0.0810 - 5.6000 |
| Volume | |
| Avg. Volume | 14,666,772 |
| Market Cap | 5.906M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.2200 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksKintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
ACCESSWIREKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway $31 million ...
PR NewswireKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
